Follow Us GraphicFacebook IconTwitter IconLinkedIn Icon
Search Graphic

Expert Financial Analysis and Reporting

Tag archive for ‘BMY’

Bristol-Myers-Squibb: Negative Market Reaction to Celgene Acquisition is a Buying Opportunity (BMY, Buy, $45.17)

Key Points Investors have turned a thumbs down on the proposed acquisition of Celgene resulting in a 14% plunge in the stock price of BMY to $45. This is because Revlimid represents about 64% of CELG sales and by 2027 or so, generic competition will erode most of its sales. The Revlimid concern was reflected […]

Northwest Biotherapeutics, Bristol-Myers Squibb: Success for the Yervoy-Opdivo Combination in CHECKMATE-214 Trial Obviously is a Major Positive for BMY, but also has Important Implications for NWBO (NWBO, Buy, $0.19) (BMY, $60.80, Buy)

The stoppage at an interim analysis of Bristol-Myers Squibb’s’ CHECKMATE-214 trial provides meaningful information into assessing the potential fro success of Northwest Biotherapeutics’ phase 3, DCVax-L trial. CHECKMATE-214 compared a combination the immunotherapy drugs Opdivo and Yervoy to Sutent (standard of care) in previously untreated, advanced or metastatic renal cell carcinoma (RCC). The trial was […]

Bristol-Myers Squibb: Disappointing Recent Press Release Causes Sharp Drop in Stock Price; I Remain at Buy (BMY, Buy, $49)

The New Press Release Bristol-Myers Squibb’s stock declined from $55.49 at the close on Thursday January 19 to $49.23 at the close on Friday January 20. This was due to a terse press release on January 20th that read “Bristol-Myers Squibb Company announced today that it has decided not to pursue an accelerated regulatory pathway […]

Bristol-Myers Squibb: Implications of Potentially Earlier than Expected Introduction of Keytruda Combined with Chemotherapy in the First Line Lung Cancer Setting (BMY, Buy, $56.31)

Investment overview Yesterday, BMY traded down sharply due to President-elect Trump’s statements on drug pricing and Merck’s announcement that the FDA has accepted a sBLA filing for the combination of Keytruda and chemotherapy (pemetrexed plus carboplatin) for the treatment of first-line metastatic or advanced non-squamous NSCLC. This report only deals with the Merck announcement. In […]

Immuno-Oncology is Probably The Most Explosive Commercial Opportunity in All of BioPharma; My Investment Picks are Bristol-Myers Squibb (BMY, Buy, $57.14) and Agenus (AGEN, Buy, $4.28))

Background Information on Checkpoint Modulation Let me provide background information that shapes my views on immuno-oncology before I get into my recommendation. The immune system has evolved over more than one billion years as a defense mechanism to protect humans and other life forms from pathogenic organisms that cause disease- notably bacteria, viruses, fungi and […]

Bristol-Myers Squibb: Checkmate-026 Trial Fails to Reach Primary Endpoint (BMY, $62.85); A Buying Opportunity

Perspective Bristol-Myers Squibb Company announced today that Opdivo had failed to reach its primary endpoint of progression free survival in the CheckMate -026 trial in first line non-small cell lung cancer. This was an open-label, study that randomized 541 patients to receive either Opdivo as monotherapy or investigator’s choice of chemotherapy. Patients enrolled in the […]

Issuance of Complete Response Letter for Eliquis Doesn’t Alter My Buy on Bristol-Myers Squibb

Investment Opinion I believe that the issuance of a Complete Response Letter to Bristol-Myers Squibb (BMY) and Pfizer (PFE) for the use of Eliquis to prevent stokes caused by atrial fibrillation is a minor setback and believe that the issue can be resolved and the product approved by October at the earliest and April of […]

FDA Cardiovascular and Renal Advisory Committee Goes Against FDA View and Recommends Approval of Xarelto

The FDA had apparently slammed the door shut on approval of Johnson & Johnson’s Xarelto (rivaroxaban) for stroke prevention in patients with non-valvular atrial fibrillation (SPAF). The FDA reviewer in his briefing papers to the committee had recommended that the product be given a Complete Response Letter (not approvable at this time). The reviewer did […]

Bristol-Myers Squibb’s Dapagliflozin Voted Down By Advisory Committee; What’s Next

Overview of Advisory Committee Meeting The FDA Endocrinologic and Metabolic Drugs Advisory Committee voted 6-9 against approval of dapagliflozin for the treatment of type II diabetes. This will almost certainly result in a Complete Response Letter from the FDA on the PDUFA date of October 28. As I pointed out in a recent report on […]